查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年淚道支架管的全球市場
市場調查報告書
商品編碼
1140677

2022-2029 年淚道支架管的全球市場

Global Lacrimal Duct Stent Tube Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

在預測期內，先進和高度成功的療法的引入將推動市場增長。

採用精確和升級的淚管設備，例如結合靈活性和強度的新型淚管插管，通過促進進入淚管來減少創傷，是市場增長的關鍵驅動力。淚道支架和淚囊切除術 (DCR) 是微創手術，在醫院範圍內的採用率顯著增加。此外，驗光師、全科醫生和進行淚道擴張和灌注的醫院對淚道支架管的需求不斷增長，預計將在未來幾年刺激產品收入。門診手術中心 (ASC) 和眼科診所等門診診所也使用淚管支架管，因為淚管治療程序簡單且成功率高。此外，使用具有成本效益的淚道支架管所獲得的有效結果正在進一步推動該行業的發展。

此外，在審查期間，患有淚管狹窄的患者數量增加正在推動對該產品的需求。鼻淚管阻塞（NLDO）或淚道狹窄是最常見的淚道系統疾病。根據 2020 年發表的論文 "Nasolacrimal Duct Obstruction" ，大約 6.0% 到 20.0% 的新生兒會出現一些症狀。NLDO 的自發恢復率很高，大約 70% 的受影響兒童在 3 個月內恢復，超過 90% 在 1 歲內恢復。在另一個例子中，20% 的健康新生兒在出生後第一年淚液引流失敗的風險很高。近年來，淚道插管已成為一種非常常見的先天性NLDO手術方法。這種手術對保守的藥物治療或不成功的探查沒有反應。還有一些與淚管阻塞相關的健康狀況，例如淚囊炎，這是一種鼻淚管炎症，通常在鼻淚管阻塞後發生。由於此類健康狀況的高發率，預計在預測期內對該產品的需求將非常高。

與淚道支架管相關的並發症預計將阻礙市場增長。

與淚道支架管相關的各種並發症可能會限制產品需求。矽膠支架的一個常見困難是管移位或橫向遷移，這很難糾正。此外，不發達國家驗光師和眼科手術醫生的短缺進一步阻礙了市場增長。

地理滲透。

北美是預測期內的主要地區。

由於其強大的醫療行業和高昂的醫療保健支出，預計北美地區將在回顧期間創下最高的市場份額。先進和現代化的醫療和眼科設施的存在以及淚腺疾病的顯著增加增加了對淚道支架管的需求。在美國和加拿大，人均醫療保健支出的增加和政府對綜合醫療保健系統的承諾的增加正在推動區域市場的增長。此外，視網膜疾病的日益流行為市場參與者提供了充足的機會。由於完善的手術設備監管框架以及公眾對淚道阻塞及相關疾病手術的意識不斷提高，美國在該地區佔據主導地位。行業公司與醫院、眼科診所建立了直接的渠道聯動，有效服務患者。此外，我們正在戰略性地收購知名診所和醫院，以擴大我們在北美的業務。

競爭格局。

由於區域和全球公司的存在，淚道支架管市場競爭適度。全球市場參與者包括 FCI Ophthalmics、Kaneka Medical America LLC、Gunther Weiss Scientific Glassblowing Co.、Aurolab、Beaver-Visitec International, Inc.領先公司正在實施各種增長戰略，如收購、產品創新和擴張，為全球淚道支架管市場的增長做出貢獻。2021 年 2 月，FCI Ophthalmics 宣布推出用於單室鼻淚管插管的 LacriJet。LacriJet 在美國推出。根據 FCI Ophthalmics 的說法，這是第一個預裝到一次性注射器中的自固位單隔室鼻淚管插管。該產品由一個一次性注射器手機組成，金屬探頭內有矽膠管。專為減少插管和拔除期間的處理時間而設計。適應症包括鼻出血、先天性鼻淚管阻塞 (CNLDO) 和鼻淚管撕裂。2020年6月，Kaneka Corporation完成了與Rohto Pharmaceutical Co., Ltd.的合作。這種夥伴關係擴大了淚管業務。兩家公司合作擴大銷售。

COVID-19 的影響將對全球淚道支架管市場產生負面影響。

鼻組織已顯示 SARS-CoV-2 病毒脫落，對鼻腔的任何干預都可能成為氣溶膠的來源。這增加了淚液外科醫生和驗光師從氣溶膠和飛沫中接觸病毒的風險。這種風險因在手術和檢測期間與患者面對面接觸而加劇，手術過程中可能出現咳嗽和打噴嚏，使醫護人員的生命處於危險之中。非緊急淚道手術和擇期淚道手術的終止影響淚道支架市場。

全球淚道支架管市場報告提供了大約 50 個市場數據表、40 個數字和 170 頁的結構。

目錄

第一章 調查方法和範圍

  • 調查方法
  • 市場範圍

第二章主要趨勢和發展

第三章執行摘要

  • 按產品劃分的市場細分
  • 最終用戶的市場細分
  • 區域市場細分

第四章市場動態

  • 市場影響因素
    • 促進者
    • 抑製劑
    • 商機
  • 影響分析

第五章行業分析

  • 波特五力分析
  • 價值鏈分析
  • 專利分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 中的價格動態
  • 供需譜
  • 大流行期間與市場相關的政府努力
  • 製造商的戰略舉措

第 7 章按產品分類

  • 單室淚道支架管
  • 雙囊淚道支架管

第 8 章最終用戶

  • 醫院
  • 眼科診所
  • 門診手術中心

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東/非洲

第 10 章 競爭格局

  • 競爭情景
  • 競爭對手戰略分析
  • 市場/份額分析
  • 併購分析

第十一章公司簡介

  • FCI Ophthalmics
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Kaneka Pharma America LLC
  • Gunther Weiss Scientific Glass
  • Bess Medizintechnik Gmbh
  • Aurolab
  • Agfa Healthcare
  • Beaver-Visitec International, Inc
  • Carefu（shandong）International Trade Co.,ltd
  • Hangzhou Formed Medical Device Co., Ltd.

第 12 章 數據管理

簡介目錄
Product Code: DMHCIT2966

Market Overview

Lacrimal Duct Stent Tube Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.2% during the forecast period (2022-2029).

Lacrimal devices are a protective ophthalmic device that helps keep the eye moist and free of dust particles. These devices are generally considered the eye's lacrimal ducts and nasal punctum. These devices play a vital role in repairing and treating lacrimal drainage systems. Lacrimal stents and intubation sets are solely used to treat epiphora both in adults and infants, obstruction, stenosis, and treat conditions necessitating dacryocystorhinostomy. Lacrimal duct stent tubes are small diameter tubes placed within the nasolacrimal system to maintain patency. Typically, the tubes are silicone or similar semi-rigid yet flexible material with an open central lumen. Nasolacrimal tubes are used primarily in lacerations or obstructing one or more parts of the tear drainage system. The global lacrimal duct stent tube market growth is augmented by increasing demand for ophthalmology treatments with better success rates, minimal invasions, and a rise in patients for nasolacrimal duct obstruction.

Market Dynamics: The introduction of advanced and high success rate treatments propel the market growth during the forecast period.

Adopting precise and upgraded lacrimal devices such as the new lacrimal cannula, which combines flexibility and strength to reduce trauma by allowing easy access to the canaliculus, is a key factor proliferating the market growth. As lacrimal duct stent tubes and dacryocystorhinostomy (DCR) surgery are minimally invasive, their adoption has significantly increased across hospitals. Moreover, the growing demand for lacrimal duct stent tubes from an optometrist or general physicians and hospitals performing lacrimal dilation and irrigation is likely to spur product revenue in the following years. Also, outpatient clinics such as ambulatory surgical centers (ASC) and ophthalmic clinics adopt lacrimal duct stent tubes due to the ease and high success rates in lacrimal treatment procedures. Additionally, effective results obtained by using cost-effective lacrimal duct stent tubes further bolster industry growth.

Moreover, the Growing number of patients suffering from dacryostenosis drives the product demand during the review period. Nasolacrimal duct obstruction (NLDO) or dacryostenosis is the most common lacrimal system disorder. According to the article 'Nasolacrimal Duct Obstruction' published in 2020, around 6.0% to 20.0% of newborn patients present with some symptoms. There is a high rate of spontaneous resolution of NLDO, with about 70% of affected children being free of the symptoms within 3 months and more than 90% recovering within a year old. In some cases, 20% of healthy newborn babies were at high risk of defective lacrimal drainage during the first year of life. Lacrimal intubation has been adopted as a very prevalent surgery for congenital NLDO in the past few years. This surgery does not respond to conservative medical treatments or failed probing. Moreover, there are other related health conditions to lacrimal duct obstruction, such as dacryocystitis, an inflammation caused in the nasolacrimal sac and is generally followed by nasolacrimal duct blockage. Due to the high incidence of such health conditions, there is significant demand for the product over the forecast timeline.

Complications related to lacrimal duct stent tubes are expected to hamper the market growth.

Various complications associated with lacrimal duct stent tubes are likely to restrain the product demand. A common difficulty with silicone stents is the displacement of tubes or lateral migration, which is difficult to correct. Also, the lack of optometrists and physicians to perform ophthalmic surgeries in underdeveloped countries further hinders market growth.

Market Segmentation: Bicanalicular lacrimal duct stent tube segment accounted for the highest share in global lacrimal duct stent tube market.

Bicanalicular lacrimal intubation has gained popularity in treating children with nasolacrimal duct obstruction, and the younger the children, the higher the success rate. Bicanalicular lacrimal tubes consist of two probes with an overriding stent. One probe is passed over the upper punctum while the other over the lower punctum. The probes are removed, and the free ends of the silicone tube are tied in the nose and are sometimes secured with a suture. The results are better with a longer duration of tube retention. This duct stent tube continues to be most-selling in the medical sector, improving patient compliance, easier usability, better clinical outcomes, and material compatibility, thus driving product demand.

Based on end-user, the lacrimal duct stent tube market is classified into hospitals, ophthalmic clinics, and ambulatory surgical centers.

The hospital segment is expected to witness the largest market share globally due to significant hospital infrastructure advancements and a rise in hospitals in emerging countries. As lacrimal stent tubes are minimally invasive with DCR procedures, their adoption in hospitals has increased considerably. A significant increase in healthcare expenditure to develop new hospitals in developed countries to provide better medical facilities offers lucrative opportunities for the market players.

Geographical Penetration: North America is the dominating region during the forecast period.

The North American region is projected to register the highest market share during the review period due to the strong medical industry and high healthcare expenditure. Advanced and modern medical and ophthalmology facilities with substantially rising lacrimal diseases increase the demand for lacrimal duct stent tubes. Growing per capita healthcare spending and favorable government initiatives for integrated healthcare systems in the U.S. and Canada drive regional market growth. Moreover, the rising number of retinal patients is creating ample opportunities for market players. The U.S. dominated the regional market due to its better regulatory framework for surgical devices and rising awareness among the population for such procedures in lacrimal duct obstruction and related health conditions. The industry players possess well-established direct channel collaboration with hospitals and ophthalmology clinics to cater to their patients effectively. Besides, the companies have strategized acquisitions with well-known clinics and hospitals to expand their business operation in North America.

Competitive Landscape:

The lacrimal duct stent tube market is moderately competitive, with the presence of regional and global players. Some global market players include FCI Ophthalmics, Kaneka Medical America LLC, Gunther Weiss Scientific Glassblowing Co., Inc., Aurolab, and Beaver-Visitec International, Inc, among others. The major players are implementing various growth strategies such as acquisitions, product innovation, and expansion, contributing to the lacrimal duct stent tube market's growth globally. In February 2021, FCI Ophthalmics Announced the Availability of LacriJet for Monocanalicular Nasolacrimal Intubation. LacriJet was launched in the United States. According to FCI Ophthalmics, it is the first self-retaining monocanalicular nasolacrimal intubation preloaded on a single-use injector. It consists of a single-use injector handpiece into which a silicone tube is preloaded inside a metallic probe. It has been specifically designed to reduce operating time during intubation and removal of the device. It is indicated for epiphora, congenital nasolacrimal duct obstruction (CNLDO), and canalicular laceration. In June 2020, Kaneka Corporation completed a partnership with Rohto Pharmaceutical Co., Ltd. This partnership helped to grow the business of lacrimal duct tubes. Both companies worked together to increase the sales of the product.

COVID-19 Impact: Negative impact on the global lacrimal duct stent tube market.

The nasal tissues have demonstrated the shedding of the SARS-CoV-2 virus, and nasal interventions are potential aerosol generators. It increases the risk of viral exposure from aerosols or droplets for lacrimal surgeons and optometrists. This risk can be further compounded by the face-to-face position with the patients during surgery or examination, possible coughing, and sneezing caused by the surgical procedures, thus risking medical practitioners' lives. The cancellation of non-urgent and elective lacrimal surgical procedures affects the lacrimal duct stent market.

The global lacrimal duct stent tube market report would provide an access to approximately 50 market data tables, 40 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by End User
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product Segment
    • 7.1.2. Market attractiveness index, By Product Segment
  • 7.2. Monocanalicular Lacrimal Duct Stent Tube *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Bicanalicular Lacrimal Duct Stent Tube

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By End User Segment
    • 8.1.2. Market attractiveness index, By End User Segment
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Ophthalmic Clinics
  • 8.4. Ambulatory Surgical Centers

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. FCI Ophthalmics*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Kaneka Pharma America LLC
  • 11.3. Gunther Weiss Scientific Glass
  • 11.4. Bess Medizintechnik Gmbh
  • 11.5. Aurolab
  • 11.6. Agfa Healthcare
  • 11.7. Beaver-Visitec International, Inc
  • 11.8. Carefu(shandong) International Trade Co.,ltd
  • 11.9. Hangzhou Formed Medical Device Co., Ltd.
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us